The DOI matches its Crossref record; 558 of the 558 references it cites were found in a registry or an index.
The Pharmacology of l-DOPA-Induced Dyskinesia in Parkinson’s Disease
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 401–558 of 558
Huang, L. Z., Campos, C., Ly, J., Carroll, F. I., & Quik, M. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.12.032 · Cited by 76
Buspirone in the treatment of levodopa induced dyskinesias.
Kleedorfer, B., Lees, A. J., & Stern, G. M. (1991) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.54.4.376-a · Cited by 76
Berger, B., & Glowinski, J. (1978) · Brain Research · doi:10.1016/0006-8993(78)90770-9 · Cited by 76
Eggert, K. M., Squillacote, D., Barone, P., Dodel, R. C., Katzenschlager, R., Emre, M., Lees, A. J., Rascol, O., Poewe, W. H., TOLOSA, E. S., et al. (2010) · Movement Disorders · doi:10.1002/mds.22974 · Cited by 76
Past, Present, and Future of the Pathophysiological Model of the Basal Ganglia
Obeso, J. A., & Lanciego, J. L. (2011) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2011.00039 · Cited by 76
Maratos, E. C., Jackson, M. J., Pearce, R. K. B., Cannizzaro, C., & Jenner, P. G. (2002) · Experimental Neurology · doi:10.1006/exnr.2002.8055 · Cited by 76
Bonsi, P., Cuomo, D., Persis, C. D., Centonze, D., Bernardi, G., Calabresi, P., & Pisani, A. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.05.012 · Cited by 75
Hill, M. P., Ravenscroft, P., Bézard, E., Crossman, A. R., Brotchie, J. M., Michel, A., Grimée, R., & Klitgaard, H. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.066191 · Cited by 74
Self-citationSilverdale, M., Kobylecki, C., Hallett, P. J., Li, Q., Dunah, A. W., Ravenscroft, P., Bézard, E., & Brotchie, J. M. (2009) · Synapse · doi:10.1002/syn.20739 · Cited by 74
Self-citationSharma, J. C., Ross, I. N., Rascol, O., & Brooks, D. J. (2008) · European Journal of Neurology · doi:10.1111/j.1468-1331.2008.02106.x · Cited by 74
L-Dopa in Parkinson's Syndrome
(1969) · New England Journal of Medicine · doi:10.1056/nejm196907312810517 · Cited by 74
Sustained Cabergoline Treatment Reverses Levodopa-Induced Dyskinesias in Parkinsonian Monkeys
Tahar, A. H., Grégoire, L., Bangassoro, E., & Bédard, P. J. (2000) · Clinical Neuropharmacology · doi:10.1097/00002826-200007000-00005 · Cited by 73
Ravenscroft, P., Chalon, S., Brotchie, J. M., & Crossman, A. R. (2003) · Experimental Neurology · doi:10.1016/j.expneurol.2003.09.001 · Cited by 72
Self-citationForced collectionism after orbitofrontal damage
Volle, E., Beato, R., Levy, R., & Dubois, B. (2002) · Neurology · doi:10.1212/wnl.58.3.488 · Cited by 71
Ostock, C. Y., Dupre, K. B., Jaunarajs, K. L. E., Walters, H., George, J. A., Krolewski, D. M., Walker, P. D., & Bishop, C. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.05.021 · Cited by 71
Crittenden, J. R., Cantuti‐Castelvetri, I., Saka, E., Keller-McGandy, C. E., Hernández, L. F., Kett, L. R., Young, A. B., Standaert, D. G., & Graybiel, A. M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812822106 · Cited by 71
Quetiapine Attenuates Levodopa-Induced Motor Complications in Rodent and Primate Parkinsonian Models
Oh, J. D., Bibbiani, F., & Chase, T. N. (2002) · Experimental Neurology · doi:10.1006/exnr.2002.8009 · Cited by 71
Nicotine Reduces l-DOPA-Induced Dyskinesias by Acting at β2* Nicotinic Receptors
Huang, L. Z., Grady, S. R., & Quik, M. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.182949 · Cited by 70
TREATMENT OF PARKINSON'S DISEASE WITH AMANTADINE AND LEVODOPA
Parkes, J. D., Curzon, G., Knott, P. J., et al. (1971) · The Lancet · doi:10.1016/s0140-6736(71)91834-4 · Cited by 69
Steinbusch, H. W. M., Sauren, Y. M. H. F., Groenewegen, H. J., et al. (1986) · Brain Research · doi:10.1016/0006-8993(86)90588-3 · Cited by 69
Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque
Bézard, E., Hill, M. P., Crossman, A. R., Brotchie, J. M., Michel, A., Grimée, R., & Klitgaard, H. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2003.11.065 · Cited by 69
Self-citationZeng, B. ‐., Jolkkonen, J., Jenner, P. G., et al. (1995) · Neuroscience · doi:10.1016/0306-4522(94)00574-o · Cited by 69
Functional Pharmacology in Human Brain
Raiteri, M. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.2.5 · Cited by 68
Thyrotropin‐releasing hormone increases GABA release in rat hippocampus
Deng, P., Porter, J. E., Shin, H., & Lei, S. (2006) · The Journal of Physiology · doi:10.1113/jphysiol.2006.118141 · Cited by 67
Koprich, J. B., Fox, S. H., Johnston, T. H., Goodman, A., Bourdonnec, B. L., Dolle, R. E., DeHaven, R. N., DeHaven‐Hudkins, D. L., Little, P., & Brotchie, J. M. (2011) · Movement Disorders · doi:10.1002/mds.23631 · Cited by 66
Self-citationMetman, L. V., Dotto, P. D., Blanchet, P. J., van den Munckhof, P., & Chase, T. N. (1998) · Amino Acids · doi:10.1007/bf01345246 · Cited by 66
Lane, E. L., Cheetham, S. C., & Jenner, P. G. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2005.06.006 · Cited by 66
Involvement of the serotonin system in l-dopa-induced dyskinesias
Carta, M., Carlsson, T., Muñoz, A., Kirik, D., & Björklund, A. (2008) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2008.04.021 · Cited by 66
Morissette, M., Dridi, M., Calon, F., Tahar, A. H., Meltzer, L. T., Bédard, P. J., & Paolo, T. D. (2005) · Movement Disorders · doi:10.1002/mds.20654 · Cited by 65
Structure and trafficking of NMDA and GABAA receptors
Stephenson, F. A. (2006) · Biochemical Society Transactions · doi:10.1042/bst0340877 · Cited by 65
Fernandez, A., CEBALLOS, M. L. D., Jenner, P. G., & MARSDEN, C. D. (1994) · Neuroscience · doi:10.1016/0306-4522(94)90061-2 · Cited by 64
Blanchet, P. J., Grondin, R., & Bédard, P. J. (1996) · Movement Disorders · doi:10.1002/mds.870110117 · Cited by 64
Effectiveness of benzodiazepines: do they work or not?
Lader, M. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.8.1189 · Cited by 63 · cited 1×
“Although the benzodiazepine diazepam effectively reduced dyskinesia in the MPTP-lesioned NHP and in a small clinical study, the use of benzodiazepines to alleviate LID might be complicated by the fact that these drugs are susceptible to tolerance, can cause sedation and dependence (Lader, 2008), and for these reasons,…”
BackgroundFariello, R. (1998) · Drugs · doi:10.2165/00003495-199855001-00002 · Cited by 63
Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease
Baronti, F., Mouradian, M. M., Davis, T. L., Giuffra, M. E., Brughitta, G., Conant, K., & Chase, T. N. (1992) · Annals of Neurology · doi:10.1002/ana.410320611 · Cited by 62
Gony, M., Lapeyre‐Mestre, M., & Montastruc, J. (2003) · Clinical Neuropharmacology · doi:10.1097/00002826-200305000-00007 · Cited by 62
Zagon, I. S., Verderame, M. F., Allen, S. S., & McLaughlin, P. J. (2000) · Brain Research · doi:10.1016/s0006-8993(99)02330-6 · Cited by 62
Bézard, E., Ravenscroft, P., Gross, C. E., Crossman, A. R., & Brotchie, J. M. (2001) · Neurobiology of Disease · doi:10.1006/nbdi.2000.0375 · Cited by 62
Self-citationLévy, R., Herrero, M. T., Ruberg, M., Villares, J., Faucheux, B. A., Guridi, J., López-Guillén, J. L., Luquín, M. R., Javoy-Agid, F., Obeso, J. A., et al. (1995) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1995.tb01110.x · Cited by 60
Effect of estrogen and progesterone on l-DOPA induced dyskinesia in MPTP-treated monkeys
Gomez‐Mancilla, B., & Bédard, P. J. (1992) · Neuroscience Letters · doi:10.1016/0304-3940(92)90152-w · Cited by 60
Patient perception of dyskinesia in Parkinson's disease
Hung, S., Adeli, G., Arenovich, T., Fox, S. H., & Lang, A. E. (2010) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.173286 · Cited by 60
Self-citationGDNF reverses priming for dyskinesia in MPTP‐treated, l ‐DOPA‐primed common marmosets
Iravani, M. M., Costa, S., Jackson, M. J., Tel, B. C., Cannizzaro, C., Pearce, R. K. B., & Jenner, P. G. (2001) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2001.01408.x · Cited by 59
Tachykinins and Neuropsychiatric Disorders
Chahl, L. A. (2006) · Current Drug Targets · doi:10.2174/138945006778019309 · Cited by 59
New non competitive AMPA antagonists
Ábrahám, G., Sólyom, S., Csuzdi, E., Berzsenyi, P., Ling, I., Tarnawa, I., Hámori, T., Pallagi, I., Horváth, K., Andrasi, F., et al. (2000) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(00)00133-4 · Cited by 59
Samadi, P., Grégoire, L., Morissette, M., Calon, F., Tahar, A. H., Bélanger, N., Dridi, M., Bédard, P. J., & Paolo, T. D. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.08.009 · Cited by 58
Martinez, A. A., Macheda, T., Morgese, M. G., Trabace, L., & Giuffrida, A. (2011) · Neuroscience Research · doi:10.1016/j.neures.2011.12.006 · Cited by 58
Oscillatory activity in the basal ganglia
Eusébio, A., & Brown, P. (2007) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(08)70044-0 · Cited by 58
Fox, S. H., Silverdale, M., Kellett, M., Davies, R., Steiger, M. J., Fletcher, N. A., Crossman, A. R., & Brotchie, J. M. (2003) · Movement Disorders · doi:10.1002/mds.10693 · Cited by 58
Self-citationFulceri, F., Biagioni, F., Ferrucci, M., Lazzeri, G., Bartalucci, A., Galli, V., Ruggieri, S. A., Paparelli, A., & Fornai, F. (2006) · Brain Research · doi:10.1016/j.brainres.2006.12.030 · Cited by 57
Newman‐Tancredi, A., Audinot, V., Chaput, C., Verrièle, L., & Millan, M. J. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36804-1 · Cited by 55
Effects of zonisamide on neurotransmitter exocytosis associated with ryanodine receptors
Yoshida, S., Okada, M., Zhu, G., & Kaneko, S. (2005) · Epilepsy Research · doi:10.1016/j.eplepsyres.2005.10.001 · Cited by 55
Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys☆
Gomez‐Mancilla, B., & Bédard, P. J. (1992) · Experimental Neurology · doi:10.1016/0014-4886(92)90125-a · Cited by 55
Acute pharmacologic blockade of dyskinesias in Parkinson's disease
Blanchet, P. J., Metman, L. V., Mouradian, M. M., et al. (1996) · Movement Disorders · doi:10.1002/mds.870110516 · Cited by 54
Hill, M. P., Bézard, E., McGuire, S. G., Crossman, A. R., Brotchie, J. M., Michel, A., Grimée, R., & Klitgaard, H. (2003) · Movement Disorders · doi:10.1002/mds.10542 · Cited by 54
Self-citationDecrease of Nicotinic Receptors in the Nigrostriatal System in Parkinson's Disease
Kas, A., Bottlaender, M., Gallezot, J., Vidailhet, M., Villafane, G., Grégoire, M., Coulon, C., Valette, H., Dollé, F., Ribeiro, M., et al. (2009) · Journal of Cerebral Blood Flow and Metabolism · doi:10.1038/jcbfm.2009.74 · Cited by 53
Miguélez, C., Aristieta, A., Cenci, M. A., & Ugedo, L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024679 · Cited by 53
Marín, C., Aguilar, E., Rodríguez-Oroz, M. C., Bartoszyk, G. D., & Obeso, J. A. (2009) · Psychopharmacology · doi:10.1007/s00213-008-1452-9 · Cited by 53
Cawello, W., Braun, M., & Boekens, H. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.027383 · Cited by 53
Fluoxetine reduces l-DOPA-derived extracellular DA in the 6-OHDA-lesioned rat striatum
Yamato, H., Kannari, K., Shen, H., et al. (2001) · Neuroreport · doi:10.1097/00001756-200105080-00015 · Cited by 51
Tison, F., Mons, N. E., Geffard, M., & Henry, P. (1991) · Journal of Neural Transmission - Parkinsons Disease and Dementia Section · doi:10.1007/bf02251134 · Cited by 51
Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias
Ouattara, B., Hoyer, D., Grégoire, L., Morissette, M., Gasparini, F., Gomez‐Mancilla, B., & Paolo, T. D. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.03.022 · Cited by 51
Samadi, P., Grégoire, L., Rassoulpour, A., Guidetti, P., Izzo, E., Schwarcz, R. M., & Bédard, P. J. (2005) · Movement Disorders · doi:10.1002/mds.20596 · Cited by 50
5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPA
Huot, P., Johnston, T. H., Winkelmolen, L., Fox, S. H., & Brotchie, J. M. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.035 · Cited by 50
Self-citationBa, M., Kong, M., Yang, H., Ma, G., Lü, G., Chen, S., & Liu, Z. (2006) · Neurochemical Research · doi:10.1007/s11064-006-9177-9 · Cited by 50
Calon, F., Morissette, M., Goulet, M., Grondin, R., Blanchet, P. J., Bédard, P. J., & Paolo, T. D. (1999) · Neurochemistry International · doi:10.1016/s0197-0186(99)00064-9 · Cited by 50
Quantification of nicotinic acetylcholine receptors in Parkinson's disease with 123I-5IA SPECT
Oishi, N., Hashikawa, K., Yoshida, H., Ishizu, K., Ueda, M., Kawashima, H., Saji, H., & Fukuyama, H. (2007) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2007.02.014 · Cited by 49
Randomized placebo-controlled study of the nicotinic agonist SIB-1508Y in Parkinson disease
The Parkinson Study Group (2006) · Neurology · doi:10.1212/01.wnl.0000196466.99381.5c · Cited by 49
van de Vijver, D. A. M. C., Roos, R. A. C., Jansen, P. A. F., Porsius, A. J., & de Boer, A. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2001.01491.x · Cited by 48
Dopamine release from serotonergic nerve fibers is reduced in L ‐DOPA‐induced dyskinesia
Nevalainen, N., af Bjerkén, S., Lundblad, M., Gerhardt, G. A., & Strömberg, I. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07292.x · Cited by 48
Arai, A., Tomiyama, M., Kannari, K., Kimura, T., Suzuki, C., Watanabe, M., Kawarabayashi, T., Shen, H., & Shoji, M. (2008) · Synapse · doi:10.1002/syn.20535 · Cited by 48
Martinez-Mir, M. I., Pollard, H., Moreau, J., Traiffort, É., Ruat, M., Schwartz, J., & Palacios, J. M. (1993) · Synapse · doi:10.1002/syn.890150306 · Cited by 48
Kuan, W., Zhao, J., & Barker, R. A. (2007) · Psychopharmacology · doi:10.1007/s00213-007-1030-6 · Cited by 48
Lindenbach, D., Ostock, C. Y., Jaunarajs, K. L. E., Dupre, K. B., Barnum, C. J., Bhide, N., & Bishop, C. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.179416 · Cited by 48
Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys
Morissette, M., Samadi, P., Tahar, A. H., Bélanger, N., & Di Paolo, T. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.12.011 · Cited by 47
Striatal neuropeptide levels in Parkinson's disease patients
Fernandez, A., CEBALLOS, M. L. D., Jenner, P., et al. (1992) · Neuroscience Letters · doi:10.1016/0304-3940(92)90014-x · Cited by 47
Lees, A. J., Shaw, K. M., & Stern, G. M. (1977) · The Lancet · doi:10.1016/s0140-6736(77)92939-7 · Cited by 47
Hurley, M. J., Jackson, M. J., Smith, L. A., Rose, S., & Jenner, P. G. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04169.x · Cited by 47
Enhanced striatal opioid receptor-mediated G-protein activation in l-dopa-treated dyskinetic monkeys
Chen, L., Togasaki, D. M., Langston, J. W., Monte, D. A. D., & Quik, M. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2004.10.026 · Cited by 46
Jackson, M. J., Smith, L. A., Al‐Barghouthy, G., Rose, S., & Jenner, P. G. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.10.005 · Cited by 46
Silverdale, M., Nicholson, S. L., Ravenscroft, P., Crossman, A. R., Millan, M. J., & Brotchie, J. M. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.03.022 · Cited by 46
Self-citationTaylor, J. L., Bishop, C., Ullrich, T., Rice, K. C., & Walker, P. D. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.12.004 · Cited by 45
Grondin, R., Bédard, P. J., Britton, D. R., & Shiosaki, K. (1997) · Neurology · doi:10.1212/wnl.49.2.421 · Cited by 45
Johnston, T. H., van der Meij, A., Brotchie, J. M., & Fox, S. H. (2010) · Movement Disorders · doi:10.1002/mds.23069 · Cited by 45
Self-citationGPR55 and the vascular receptors for cannabinoids
Hiley, C. R., & Kaup, S. S. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707421 · Cited by 44
Effects of supra-threshold levodopa doses on dyskinesias in advanced Parkinson's disease
Metman, L. V., van den Munckhof, P., Klaassen, A. A. G., Blanchet, P. J., Mouradian, M. M., & Chase, T. N. (1997) · Neurology · doi:10.1212/wnl.49.3.711 · Cited by 44
Marı́n, C., Aguilar, E., Bonastre, M., et al. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2004.10.008 · Cited by 44
Hurley, M. J., Jolkkonen, J., Stubbs, C. M., et al. (1996) · Brain Research · doi:10.1016/0006-8993(95)01309-1 · Cited by 44
Huot, P., Johnston, T. H., Koprich, J. B., Aman, A. M., Fox, S. H., & Brotchie, J. M. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.195693 · Cited by 44
Self-citationHuot, P., Fox, S. H., Newman‐Tancredi, A., & Brotchie, J. M. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.184093 · Cited by 44
Self-citationHsu, A., Togasaki, D. M., Bézard, E., Sokoloff, P., Langston, J. W., Monte, D. A. D., & Quik, M. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.071142 · Cited by 44
Morissette, M., Dridi, M., Calon, F., Tahar, A. H., Meltzer, L. T., Bédard, P. J., & Paolo, T. D. (2006) · Synapse · doi:10.1002/syn.20295 · Cited by 43
Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaque
Huot, P., Johnston, T. H., Koprich, J. B., Winkelmolen, L., Fox, S. H., & Brotchie, J. M. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.09.011 · Cited by 43
Self-citationEffect of l‐Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys
Ouattara, B., Gasparini, F., Morissette, M., Grégoire, L., Samadi, P., Gomez‐Mancilla, B., & Paolo, T. D. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06635.x · Cited by 43
Adenosine A2A receptor mRNA expression in Parkinson's disease
Hurley, M. J., Mash, D. C., & Jenner, P. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01371-9 · Cited by 42
Tamim, M. K., Samadi, P., Morissette, M., Grégoire, L., Ouattara, B., Lévesque, D., Rouillard, C., & Paolo, T. D. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.06.030 · Cited by 42
Kampen, J. M. V., & Stoessl, A. J. (2003) · Neuroscience · doi:10.1016/s0306-4522(02)00548-1 · Cited by 41
Padovan‐Neto, F. E., Echeverry, M. B., Chiavegatto, S., & Bel, E. A. D. (2011) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2011.00040 · Cited by 41
Human brain dopamine metabolism in levodopa-induced dyskinesia and wearing-off
Rajput, A. H., Fenton, M. E., Paolo, T. D., Sitte, H. H., Pifl, C., & Hornykiewicz, O. (2004) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2004.01.004 · Cited by 40
Johnston, T. H., Huot, P., Fox, S. H., WAKEFIELD, J. D., Sykes, K. A., Bartolini, W. P., Milne, G. T., Pearson, J. P., & Brotchie, J. M. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.169532 · Cited by 40
Self-citationl-DOPA Impairs Proteasome Activity in Parkinsonism through D1Dopamine Receptor
Berthet, A., Bézard, E., Porras, G., Fasano, S., Barroso‐Chinea, P., Dehay, B., Martínez, A., Thiolat, M.-L., Nosten‐Bertrand, M., Giros, B., et al. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.1541-11.2012 · Cited by 40
Corticomuscular coherence is increased in the small postural tremor of Parkinson's disease
Caviness, J. N., Shill, H. A., Sabbagh, M. N., Evidente, V. G. H., Hernández‐Davó, J. L., & Adler, C. H. (2005) · Movement Disorders · doi:10.1002/mds.20743 · Cited by 39
Serotonin 1B receptor stimulation reduces D1 receptor agonist-induced dyskinesia
Jaunarajs, K. L. E., Dupre, K. B., Steiniger, A., Klioueva, A., Moore, A., Kelly, C., & Bishop, C. (2009) · Neuroreport · doi:10.1097/wnr.0b013e3283300fd7 · Cited by 39
Buspirone in Parkinsonʼs Disease
Hammerstad, J. P., Carter, J., Nutt, J. G., Casten, G. C., Shrotriya, R. C., Alms, D. R., & TEMPLE, D. L. J. (1986) · Clinical Neuropharmacology · doi:10.1097/00002826-198612000-00007 · Cited by 39
Nicotinic excitation of serotonergic projections from dorsal raphe to the nucleus accumbens
Chang, B., Daniele, C. A., Gallagher, K., Madonia, M., Mitchum, R. D., Barrett, L. E., Vezina, P., & McGehee, D. S. (2011) · Journal of Neurophysiology · doi:10.1152/jn.00575.2010 · Cited by 38
Quik, M., Police, S. M. C., Langston, J. W., & Monte, D. A. D. (2002) · Neuroscience · doi:10.1016/s0306-4522(02)00167-7 · Cited by 38
ACP-103, a 5-HT2A receptor inverse agonist.
Roberts, C. (2006) · PubMed · Cited by 38
Calon, F., Morissette, M., Goulet, M., Grondin, R., Blanchet, P. J., Bédard, P. J., & Paolo, T. D. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7366 · Cited by 37
Nur77 mRNA levels and L-Dopa-induced dyskinesias in MPTP monkeys treated with docosahexaenoic acid
Mahmoudi, S., Samadi, P., Gilbert, F., Ouattara, B., Morissette, M., Grégoire, L., Rouillard, C., Paolo, T. D., & Lévesque, D. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.017 · Cited by 37
Samadi, P., Grégoire, L., & Bédard, P. J. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.02.002 · Cited by 36
Visanji, N., Fox, S. H., Johnston, T., Millan, M., & Brotchie, J. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.144097 · Cited by 36
Self-citationMetabotropic Glutamate Receptor II in the Brains of Parkinsonian Patients
Samadi, P., Rajput, A. H., Calon, F., Grégoire, L., Hornykiewicz, O., Rajput, A. H., & Paolo, T. D. (2009) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31819cabe4 · Cited by 36
Acidosis has opposite effects on neuronal survival during hypoxia and reoxygenation
Almaas, R., Pytte, M., Lindstad, J. K., Wright, M., Saugstad, O. D., Pleasure, D., & Rootwelt, T. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01593.x · Cited by 35
Effects of Dopamine Denervation on Striatal Peptide Expression in Parkinsonian Monkeys
Lavoie, B. A., Parent, A., & Bédard, P. J. (1991) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100032467 · Cited by 34
Open Pilot Trial of Ritanserin in Parkinsonism
de Noordhout, A. M., & Delwaide, P. J. (1986) · Clinical Neuropharmacology · doi:10.1097/00002826-198610000-00010 · Cited by 33
Differential effects of endocannabinoids on [3H]-GABA uptake in the rat globus pallidus
Venderová, K., Brown, T. M., & Brotchie, J. M. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2005.02.012 · Cited by 33
Self-citationInteraction of zonisamide with benzodiazepine and GABA receptors in rat brain.
Mimaki, T., Suzuki, Y., Tagawa, T., Karasawa, T., & Yabuuchi, H. (1990) · PubMed · Cited by 31
Subhypnotic doses of zolpidem oppose dopaminergic-induced dyskinesia in Parkinson's disease
R??i?ka, E., Roth, J., Jech, R., & ek, P. B. (2000) · Movement Disorders · doi:10.1002/1531-8257(200007)15:4<734::aid-mds1022>3.0.co;2-e · Cited by 31
Glutamate release inhibition ineffective in Levodopa‐induced motor complications
Bara‐Jimenez, W., Dimitrova, T. D., Sherzai, A., Aksu, M., & Chase, T. N. (2006) · Movement Disorders · doi:10.1002/mds.20976 · Cited by 31
Endogenous morphine-like compound immunoreactivity increases in parkinsonism
Charron, G., Doudnikoff, É., Laux‐Biehlmann, A., Berthet, A., Porras, G., Canron, M., Barroso‐Chinea, P., Li, Q., Qin, C., Nosten‐Bertrand, M., et al. (2011) · Brain · doi:10.1093/brain/awr166 · Cited by 31
Marı́n, C., Aguilar, E., & Obeso, J. A. (2006) · Movement Disorders · doi:10.1002/mds.20780 · Cited by 30
Levodopa but not ropinirole induces an internalization of D1 dopamine receptors in parkinsonian rats
Muriel, M., Orieux, G., & Hirsch, É. C. (2002) · Movement Disorders · doi:10.1002/mds.10256 · Cited by 30
Stockwell, K., Scheller, D., Smith, L. A., Rose, S., Iravani, M., Jackson, M., & Jenner, P. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.10.004 · Cited by 29
Pérez, V., Marín, C., Rubio, A., Aguilar, E., Barbanoj, M. J., & Kulisevsky, J. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0291-0 · Cited by 29
Controlled Release Levodopa-Carbidopa (CR-5) in the Management of Parkinsonian Motor Fluctuations
Juncos, J. L., Fabbrini, G., Mouradian, M. M., & Chase, T. N. (1987) · Archives of Neurology · doi:10.1001/archneur.1987.00520220016008 · Cited by 29
Tayarani‐Binazir, K. A., Jackson, M. J., Rose, S., Olanow, C. W., & Jenner, P. G. (2010) · Movement Disorders · doi:10.1002/mds.22960 · Cited by 28
Sander, S. E., Lemm, C., Lange, N., Hamann, M., & Richter, A. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.10.016 · Cited by 28
Buck, K., & Ferger, B. (2009) · Synapse · doi:10.1002/syn.20709 · Cited by 27
Controlled release levodopa treatment of motor fluctuations in Parkinson's disease.
Juncos, J. L., Fabbrini, G., Mouradian, M. M., et al. (1987) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.50.2.194 · Cited by 27
Clinical studies with and pharmacokinetic considerations of sustained-release levodopa.
LeWitt, P. A. (1992) · PubMed · Cited by 24
In vitro evaluation of nicotinic acetylcholine receptors with 2-[18F]F-A85380 in Parkinson's disease
Schmaljohann, J., Gündisch, D., Minnerop, M., Bucerius, J. A., Joe, A., Reinhardt, M. J., Guhlke, S., Biersack, H., & Wüllner, U. (2006) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2005.12.012 · Cited by 24
Levetiracetam Interferes With the l-Dopa Priming Process in MPTP-Lesioned Drug-Naive Marmosets
Hill, M. P., Brotchie, J. M., Crossman, A. R., Bézard, E., Michel, A., Grimée, R., & Klitgaard, H. (2004) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000135478.70905.3d · Cited by 24
Self-citationStriatal delta opioid receptor binding in experimental models of Parkinson's disease and dyskinesia
Hallett, P. J., & Brotchie, J. M. (2006) · Movement Disorders · doi:10.1002/mds.21163 · Cited by 23
Self-citationModulation of the clozapine structure increases its selectivity for the dopamine D4 receptor
Liégeois, J., Bruhwyler, J., Damas, J., Rogister, F. A., Masereel, B., Géczy, J., & Delarge, J. (1995) · European Journal of Pharmacology · doi:10.1016/0014-2999(94)00782-3 · Cited by 23
ALAGARSAMY, S., Rouse, S. T., Gereau, R. W., Heinemann, S. F., Smith, Y., & Conn, P. J. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb11321.x · Cited by 23
Meco, G., Marini, S., Lestingi, L., Linfante, I., Modarelli, F., & AGNOLI, A. (1988) · Current Therapeutic Research · Cited by 23
Papathanou, M., Rose, S., McCreary, A. C., & Jenner, P. G. (2011) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2011.07704.x · Cited by 22
Ansah, T. A., Ferguson, M. C., & Nayyar, T. (2011) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2011.00048 · Cited by 22
LONG-LASTING DYSKINESIA INDUCED BY LEVODOPA
Weiss, J. L., Ng, L. Y., & Chase, T. (1971) · The Lancet · doi:10.1016/s0140-6736(71)91410-3 · Cited by 22
Silverdale, M., Crossman, A. R., & Brotchie, J. M. (2002) · Experimental Neurology · doi:10.1006/exnr.2001.7854 · Cited by 21
Self-citationl-DOPA treatment of parkinsonian rats changes the expression of Src, Lyn and PKC kinases
Napolitano, M., Picconi, B., Centonze, D., Bernardi, G., Calabresi, P., & Gulino, A. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2005.12.077 · Cited by 20
Carta, A. R., Frau, L., Pinna, A., & Morelli, M. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.04.016 · Cited by 18
Antidyskinetic effect of JL-18, a clozapine analog, in parkinsonian monkeys
Tahar, A. H., Bélanger, N., Bangassoro, E., Grégoire, L., & Bédard, P. J. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00310-1 · Cited by 17
Controlled Release Levodopa/Carbidopa 25/100 (Sinemet CR 25/100)
Hammerstad, J. P., Woodward, W. R., Nutt, J. G., et al. (1994) · Clinical Neuropharmacology · doi:10.1097/00002826-199410000-00005 · Cited by 17
Dyskinesias in normal squirrel monkeys induced by nomifensine and levodopa
Togasaki, D. M., Protell, P., TAN, L., WILLIAMLANGSTON, J., Monte, D. A. D., & Quik, M. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.10.009 · Cited by 16
Traub, M., Wagner, H. R., Hassan, M., Jackson-Lewis, V. R., & Fahn, S. (1985) · European Journal of Pharmacology · doi:10.1016/0014-2999(85)90673-9 · Cited by 16
Systemic administration of thyrotropin-releasing hormone enhances striatal dopamine release in vivo
Kreutz, M. R., Acworth, I. N., Lehnert, H., & Wurtman, R. J. (1990) · Brain Research · doi:10.1016/0006-8993(90)90049-h · Cited by 16
Huot, P., & Brotchie, J. M. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2011.07.006 · Cited by 14
Self-citationCa2+ mobilizing agents mimic serotonin 5-HT2 facilitation of N-methyl-D-aspartate depolarization
Neuman, R. S., & Rahman, S. (1995) · Behavioural Brain Research · doi:10.1016/0166-4328(96)00111-8 · Cited by 13
Tsironis, C. N., Μαρσέλος, Μ., Evangelou, A. M., & Konitsiotis, S. (2008) · Movement Disorders · doi:10.1002/mds.21630 · Cited by 12
Berger, B. (1978) · PubMed · Cited by 12
New insights into the organization of the basal ganglia
Koprich, J. B., Johnston, T. H., Huot, P., Fox, S. H., & Brotchie, J. M. (2009) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-009-0045-2 · Cited by 11
Self-citationActivation of the Proopiomelanocortin Gene with Ketoconazole as a Treatment for Parkinson's Disease
Bucay, A. H. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1418.013 · Cited by 11
Samadi, P., Morissette, M., Calon, F., Tahar, A. H., Dridi, M., Bélanger, N., Meltzer, L. T., Bédard, P. J., & Paolo, T. D. (2007) · Synapse · doi:10.1002/syn.20469 · Cited by 11
Iravani, M. M., Costa, S., Al‐Bargouthy, G., Jackson, M. J., Zeng, B., Kuoppamäki, M., Obeso, J. A., & Jenner, P. G. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04308.x · Cited by 10
Nondopaminergic Treatments for Parkinson’s Disease
Huot, P., & Fox, S. H. (2011) · Neurodegenerative Disease Management · doi:10.2217/nmt.11.62 · Cited by 10
Self-citationCotzias, G. C. (1969) · Journal of Chronic Diseases · doi:10.1016/0021-9681(69)90072-1 · Cited by 10
Positive reinforcing effects of flupirtine — Two case reports
Stoessel, C., Heberlein, A., Hillemacher, T., Bleich, S., & Kornhuber, J. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.03.031 · Cited by 7
Waldvogel (1999) · doi:10.1002/1531-8249(199907)46:1
Cited by
Dopamine-loaded blood exosomes targeted to brain for better treatment of Parkinson’s disease
Qu, M., Lin, Q., Huang, L., Fu, Y., Wang, L., He, S., Fu, Y., Yang, S., Zhang, Z., Zhang, L., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.08.035 · Cited by 543
Levodopa‐induced dyskinesia in Parkinson disease: Current and evolving concepts
Espay, A. J., Morgante, F., Merola, A., Fasano, A., Marsili, L., Fox, S. H., Bezard, E., Picconi, B., Calabresi, P., & Lang, A. E. (2018) · Annals of Neurology · doi:10.1002/ana.25364 · Cited by 340
Self-citationCilia, R., Akpalu, A., Sarfo, F. S., Cham, M., Amboni, M., Cereda, E., Fabbri, M., Adjei, P., Akassi, J., Bonetti, A., et al. (2014) · Brain · doi:10.1093/brain/awu195 · Cited by 339
Balancing mTOR Signaling and Autophagy in the Treatment of Parkinson’s Disease
Zhu, Z., Yang, C., Iyaswamy, A., Krishnamoorthi, S., Sreenivasmurthy, S. G., Liu, J., Wang, Z., Tong, B. C.-K., Song, J., Lu, J., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030728 · Cited by 263
Bortolanza, M., do Nascimento, G. C., Raisman‐Vozari, R., & Del‐Bel, E. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15439 · Cited by 33
Metadata
- Authors
- Huot, P., Johnston, T. H., Koprich, J. B., Fox, S. H., & Brotchie, J. M.
- Venue
- Pharmacological Reviews
- Publisher
- Elsevier BV
- Published
- 2013-01
- Volume
- 65
- Issue
- 1
- Pages
- 171-222
- ISSN
- 0031-6997 (ISSN-L)
- OpenAlex
- W2107758668
- Cited by
- 324
- References
- 558
- FWCI
- 21.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.